Page 23 - 《中国药房》2024年5期
P. 23

·药学研究·


          熊果苷对心肌纤维化模型大鼠的改善作用及机制研究
                                                                                            Δ

          张明昊 ,吴星霏,吴刘俊,申艳朵,张家乐,谢秉恒,王瑾瑾(河南中医药大学医学院,郑州 450046)
                *
                                                              #
          中图分类号  R965;R285.5      文献标志码  A      文章编号  1001-0408(2024)05-0529-07
          DOI  10.6039/j.issn.1001-0408.2024.05.04

          摘  要  目的  研究熊果苷对心肌纤维化(MF)模型大鼠的改善作用及机制。方法  采用网络药理学方法预测熊果苷改善MF的
          潜在靶点并进行分子对接验证。将50只SD大鼠皮下注射异丙肾上腺素(5 mg/kg,每天1次,连续14 d)复制MF模型。将造模成
          功的大鼠随机分为模型组、卡托普利组(9 mg/kg)和熊果苷低、中、高剂量组(50、100、200 mg/kg),每组10只;另取10只未造模大鼠
          作为正常组。各组大鼠给予相应药物干预,每天1次,连续28 d。末次给药24 h后,检测大鼠心电图、心脏相关指数[心脏质量指数
         (HWI)、左心室质量指数(LVWI)],检测大鼠心肌组织中肌酸激酶(CK)、乳酸脱氢酶(LDH)、N末端前脑钠肽前体(NT-proBNP)、
          Ⅰ型胶原蛋白(Col Ⅰ)、Col Ⅲ水平,观察大鼠心肌组织病理形态学变化,检测大鼠心肌组织中腺苷脱氨酶(ADA)、腺苷激酶
         (ADK)蛋白及其mRNA表达水平。结果  网络药理学结果显示,熊果苷改善MF的主要靶点为ADA、ADK。分子对接结果显示,
          熊果苷与ADA、ADK结合稳定。验证实验结果显示,与模型组比较,各给药组大鼠心电图ST波段和T波的振幅有所恢复,心房出
          现扑动的症状减轻;HWI(熊果苷中剂量组除外)、LVWI和心肌组织中CK、LDH、NT-proBNP、Col Ⅰ、Col Ⅲ水平均显著降低(P<
          0.05);大鼠心肌纤维化程度减轻;心肌组织中ADA、ADK蛋白及其mRNA表达水平均显著升高(P<0.05)。结论  熊果苷可改善
          MF 模型大鼠心脏纤维化和心脏功能,其作用机制可能与上调 ADA、ADK 蛋白及其 mRNA 表达,影响核苷酸代谢及胶原生成
          有关。
          关键词  熊果苷;心肌纤维化;网络药理学;腺苷脱氨酶;腺苷激酶

          Improvement effect of arbutin on myocardial fibrosis model rats and its mechanism
          ZHANG Minghao,WU Xingfei,WU Liujun,SHEN Yanduo,ZHANG Jiale,XIE Bingheng,WANG Jinjin
         (Medical College, Henan University of Chinese Medicine, Zhengzhou 450046, China)

          ABSTRACT   OBJECTIVE  To  study  the  improvement  effects  of  arbutin  on  myocardial  fibrosis (MF)  model  rats  and  its
          mechanism.  METHODS  The  network  pharmacology  was  used  to  predict  the  potential  target  of  arbutin  in  improving  MF  and
          molecular docking was used to validated. Totally 50 SD rats were given isoprenaline subcutaneously (5 mg/kg, once a day, for 14
          consecutive  days)  to  induce  the  MF  model.  Modeled  rats  were  randomly  divided  into  model  group,  captopril  group (9  mg/kg),
          arbutin low-dose, medium-dose and high-dose groups (50, 100, 200 mg/kg), with 10 rats in each group. Another 10 healthy rats
          were included as normal group. Each group was given the corresponding drugs, once a day, for 28 consecutive days. Twenty-four
          hours after the final administration, electrocardiograms and heart-related indexes [heart weight index (HWI), left ventricular weight
          index (LVWI)]  of  rats  were  detected;  the  levels  of  creatine  kinase (CK),  lactate  dehydrogenase (LDH),  N-terminal  pro-brain
          natriuretic  peptide (NT-proBNP)  and  type  Ⅰ  collagen (Col  Ⅰ)  and  Col  Ⅲ  were  detected  in  myocardial  tissue  of  rats;  the
          pathological  changes  of  myocardial tissue  were  observed,  and  protein  and  mRNA  expressions  of  adenosine  deaminase (ADA)  and
          adenosine  kinase (ADK)  were  detected  in  the  myocardial  tissue  of  rats.  RESULTS  The  results  of  network  pharmacology  showed
          that  the  main  targets  of  arbutin  improving  MF  were  ADA  and  ADK.  The  results  of  molecular  docking  showed  that  arbutin  bind
          stably with ADA and ADK. The results of experimental verification showed that compared with model group, the amplitude of ST
          and T waves in electrocardiogram were improved in administration groups, and the symptoms of atrial flutter were alleviated; HWI
         (except  for  arbutin  medium-dose  group),  LVWI,  the  levels  of  CK,  LDH,  NT-proBNP,  Col  Ⅰ  and  Col  Ⅲ  in  the  myocardial
          tissue  of  rats  were  decreased  significantly (P<0.05);  the  degree  of  myocardial  fibrosis  in  rats  decreased;  protein  and  mRNA
          expressions  of  ADA  and  ADK  in  the  myocardial  tissue  were  significantly  increased (P<0.05).  CONCLUSIONS  Arbutin  can
                                                             improve  cardiac  fibrosis  and  cardiac  function  of  MF  model
             Δ 基金项目 国家自然科学基金项目(No.82104748);河南省自然
                                                             rats,  the  mechanism  of  which  may  be  associated  with  up-
          科学基金项目(No.202300410253);河南省高等学校青年骨干教师培
                                                             regulating  protein  and  mRNA  expressions  of  ADA  and  ADK,
          养计划(No.2020GGJS109)                                influencing the nucleotide metabolism and collagen generation.
             *第一作者 高级实验师,硕士。研究方向:基础药理学。E-mail:
          zhangminghao@hactcm.edu.cn                         KEYWORDS     arbutin; myocardial fibrosis; network pharma-
             #  通信作者 副 教 授 ,博 士 。 研 究 方 向 :预 防 医 学 。 E-mail:  cology; adenosine deaminase; adenosine kinase
          wangjinjin@hactcm.edu.cn


          中国药房  2024年第35卷第5期                                                 China Pharmacy  2024 Vol. 35  No. 5    · 529 ·
   18   19   20   21   22   23   24   25   26   27   28